SPAC IPO Weekly Update: June 10, 2018
by Kristi Marvin on 2018-06-10 at 10:36am

Current Universe of SPACs Seeking a Target

Click on the green Download sign found at the bottom left of the table.
[embeddoc url=”https://spacinsider.com/wp-content/uploads/2018/06/SPAC-Weekly-Update-6-10-2018.pdf” download=”all” viewer=”google”]

SPAC IPO Weekly Update: June 10, 2018
Recent Posts
by Nicholas Alan Clayton on 2025-06-26 at 7:04pm

FIGX Acquisition Corp. (NASDAQ:FIGXU) announced the pricing of its $131 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “FIGXU”, Friday, June 27, 2025. The new SPAC aims to seek out a financial services target with a particular focus on wealth and asset managers with the potential to...

by Nicholas Alan Clayton on 2025-06-26 at 4:52pm

Yorkville Acquisition Corp. (NASDAQ:YORKU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “YORKU”, Friday, June 27, 2025. The new SPAC plans to combine with a target company in the telecom, media or technology sectors. Yorkville Acquisition Corp.’s management team is led...

by Nicholas Alan Clayton on 2025-06-26 at 8:24am

At the SPAC of Dawn As pressure on Fed Chairman Jerome Powell increases, the market is set to ingest a raft of new indicators today as well as hear from Cleveland Fed President Beth Hammack on the potential interest rate path. Today will also see June’s 8th SPAC IPO as Cantor Equity Partners III Inc....

by Nicholas Alan Clayton on 2025-06-25 at 6:30pm

Cantor Equity Partners III Inc. (NASDAQ:CAEP) announced the pricing of its upsized $240 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “CAEP”, Thursday, June 26, 2025. The new SPAC plans to combine with a target company in an industry where its management has relevant expertise such financial...

by Nicholas Alan Clayton on 2025-06-25 at 12:44pm

Launch One (NASDAQ:LPAA) has entered into a definitive agreement to combine with biotech firm Minovia Therapeutics at a $180 million pre-money valuation. Haifa, Israel-based Minovia is developing a drug platform based on mitochondrial cell therapies to potentially treat rare disorders as well as the effects of aging and other causes of bodily degeneration. The combined...

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved